Hester Biosciences Ltd

BSE: HESTERBIO524669ISIN INE782E01017

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹2,318.85+58.15 (+2.57%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹2,669.00
52W low: ₹1,250.95
Off 52W high: -13.12%
1M return: +10.12%
3M return: -4.83%
6M return: +40.01%
1Y return: +44.58%
20D avg volume: 159
50 DMA: ₹2,215.54
200 DMA: ₹1,926.27

Key ratios Consolidated

Market cap: ₹1,973 Cr
Current price: ₹2,318.85
52W high / low: ₹2,669.00 / ₹1,250.95
Face value: ₹10.00
P/E: 14.41
P/B: 5.48
EPS (TTM): ₹160.95
Book value / share: ₹423.46
ROE: —
ROCE: 15.30%
Operating margin: —
Net margin: —
Debt / equity: 0.51
Net debt: ₹185.48 Cr
Interest cover: 7.36
Dividend yield: 0.47%
Dividend / share (TTM): ₹11.00
Payout: 6.83%
Cash conversion cycle: 157.1 days

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	77.24	100.11	77.42	70.97	84.11	81.92	63.22	83.69	82.27	79.25	66.98	70.45
	1.64	-3.03	0.67	9.73	2.32	-6.95	7.81	1.84	1.23	4.14	0.99	4.36
	78.89	97.08	78.08	80.70	86.42	74.97	71.03	85.53	83.49	83.40	67.97	74.81
	64.59	76.79	65.88	65.81	67.28	72.54	58.64	74.62	73.76	74.01	62.77	69.60
	13.72	21.30	18.34	17.43	13.56	15.56	16.53	15.90	15.95	14.47	13.34	14.29
	5.66	5.65	5.65	0.14	4.59	4.70	4.79	3.02	5.09	6.41	5.96	6.02
	14.88	16.37	15.52	15.50	15.28	14.19	16.34	15.89	16.00	16.10	15.58	16.45
	3.08	5.09	1.82	2.21	1.81	5.62	3.81	5.89	5.01	6.94	2.19	8.07
	7.04	5.91	4.43	4.35	4.18	4.18	4.29	4.20	4.13	3.74	3.75	4.28
	22.50	29.96	23.38	24.43	23.55	27.81	22.19	24.12	25.18	25.69	20.61	21.27
	14.30	20.30	12.21	14.88	19.14	2.44	12.39	10.91	9.73	9.39	5.20	5.21
	85.35	2.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	99.64	23.23	12.21	14.88	19.14	2.44	12.39	10.91	9.73	9.39	5.20	5.21
	4.95	8.54	4.21	2.71	2.89	2.20	1.96	3.48	3.11	3.47	2.39	2.72
	96.73	16.55	9.31	14.33	17.30	1.54	11.41	8.39	7.49	6.39	4.02	4.04
	113.71	19.45	10.94	16.85	20.33	1.82	13.41	9.86	8.80	7.52	4.73	4.75
Key metrics
	109.76	34.23	18.46	21.44	25.13	12.24	20.49	21.00	18.87	20.07	11.14	17.56
	142.10%	34.20%	23.80%	30.20%	29.90%	14.90%	32.40%	25.10%	22.90%	25.30%	16.60%	24.90%
	125.20%	16.50%	12.00%	20.20%	20.60%	1.90%	18.00%	10.00%	9.10%	8.10%	6.00%	5.70%
	—	5.40%	—	3.20%	—	1.50%	—	—	—	—	—	—
	-8.20%	22.20%	22.50%	-15.20%	2.20%	3.40%	-5.60%	18.80%	—	—	—	—
	459.10%	974.70%	-18.40%	70.80%	131.00%	-75.90%	183.80%	107.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	325.74	332.60	311.10	304.55	266.09	235.01
	9.01	9.68	3.92	10.64	15.15	13.74
	334.75	342.28	315.03	315.18	281.24	248.75
	273.07	275.76	279.56	287.84	245.50	195.67
	70.79	70.62	63.95	54.31	52.99	60.65
	17.10	15.74	17.60	32.82	29.75	12.62
	62.27	62.67	62.42	64.13	56.02	45.33
	12.20	10.93	12.70	19.77	9.32	4.06
	21.73	18.88	16.80	17.17	20.70	16.58
	100.27	101.31	99.30	90.88	—	—
	61.69	66.53	35.47	27.34	35.74	53.08
	88.29	2.94	0.00	0.00	0.00	0.00
	149.96	69.46	35.47	27.34	35.74	53.08
	20.41	18.35	10.74	10.79	12.12	14.02
	136.92	57.48	28.83	21.17	28.04	39.48
	160.95	67.57	33.89	24.88	32.96	46.41
Key metrics
	183.89	99.27	64.97	64.28	65.76	73.72
	56.45%	29.80%	20.90%	21.10%	24.70%	31.40%
	42.03%	17.30%	9.30%	7.00%	10.50%	16.80%
	—	15.30%	9.10%	—	—	—
	4.09%	6.90%	2.20%	14.50%	13.20%	—
	254.35%	99.40%	36.20%	-24.50%	-29.00%	—
	—	46.31	43.92	—	—	—
	—	1.12	2.24	—	—	—
	—	0.51	0.64	—	—	—
	—	185.48	202.19	—	—	—
	—	157.1	134.0	—	—	—
Balance sheet
	—	677.94	653.38	—	—	—
	—	208.56	195.17	—	—	—
	—	2.77	5.59	—	—	—
	—	95.36	73.18	—	—	—
	—	72.53	70.38	—	—	—
	—	13.08	18.47	—	—	—
	—	411.06	232.68	—	—	—
	—	24.68	29.42	—	—	—
	—	152.48	125.18	—	—	—
	—	188.25	207.78	—	—	—
	—	98.29	74.41	—	—	—
	—	89.96	133.37	—	—	—
	—	367.79	326.66	—	—	—
Cash flow
	—	64.14	64.51	—	—	—
	—	-3.29	-19.00	—	—	—
	—	-48.79	-51.72	—	—	—
	—	17.83	20.59	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	72.66	93.71	70.35	64.58	63.49	76.67	62.83	73.50	73.47	72.87	65.50	66.43
	1.68	4.18	1.03	1.48	0.95	1.06	1.30	1.35	1.06	1.20	0.98	1.22
	74.34	97.89	71.39	66.05	64.44	77.73	64.13	74.85	74.52	74.08	66.48	67.65
	54.59	70.02	56.75	56.17	54.15	66.25	57.64	62.37	63.22	63.85	57.87	58.49
	10.79	16.51	11.31	9.71	8.68	9.02	8.44	10.81	10.59	9.17	6.65	8.43
	5.52	9.83	12.84	7.84	8.93	13.64	12.01	9.26	9.93	13.59	13.57	11.68
	13.18	14.00	12.91	13.02	13.24	12.14	14.31	14.11	14.21	14.32	13.61	14.66
	1.36	4.09	0.90	1.27	0.91	1.25	1.59	1.40	1.13	1.31	1.37	1.48
	4.92	3.68	2.21	2.20	2.16	2.03	2.24	2.19	2.12	2.08	2.57	2.58
	19.17	27.90	19.35	18.92	18.35	24.89	19.32	20.07	22.81	22.86	18.67	19.41
	19.75	27.87	14.64	9.88	10.29	11.48	6.49	12.48	11.30	10.22	8.61	9.16
	0.00	7.00	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	19.75	34.87	14.64	9.88	10.29	11.48	6.49	12.48	11.30	10.22	8.61	9.16
	5.04	8.49	3.97	2.67	2.45	1.85	2.05	3.15	2.87	2.79	2.14	2.38
	14.71	26.38	10.67	7.21	7.84	9.63	4.44	9.34	8.43	7.43	6.47	6.78
	17.29	31.01	12.54	8.48	9.21	11.33	5.22	10.97	9.91	8.74	7.61	7.97
Key metrics
	26.03	42.64	17.75	13.35	13.36	14.76	10.32	16.07	14.55	13.61	12.55	13.22
	35.80%	45.50%	25.20%	20.70%	21.00%	19.30%	16.40%	21.90%	19.80%	18.70%	19.20%	19.90%
	20.20%	28.20%	15.20%	11.20%	12.30%	12.60%	7.10%	12.70%	11.50%	10.20%	9.90%	10.20%
	—	8.40%	—	2.50%	—	2.80%	—	—	—	—	—	—
	14.40%	22.20%	12.00%	-12.10%	-13.60%	5.20%	-4.10%	10.60%	—	—	—	—
	87.60%	173.90%	140.30%	-22.80%	-7.00%	29.60%	-31.40%	37.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	301.30	292.14	286.47	285.15	254.00	219.35
	8.37	7.63	4.76	4.26	5.32	4.66
	309.67	299.77	291.23	289.42	259.32	224.01
	237.53	237.09	249.47	252.69	215.40	170.75
	48.32	46.22	38.86	32.69	29.28	34.93
	36.03	39.44	44.84	56.59	55.37	39.30
	53.11	53.17	54.76	56.72	47.92	39.12
	7.62	7.17	5.37	5.09	6.50	2.47
	13.01	10.25	8.58	9.78	9.79	9.50
	85.34	84.52	87.10	81.45	71.32	—
	72.14	62.69	41.76	36.73	43.92	53.26
	7.00	7.00	0.00	—	—	—
	79.14	69.68	41.76	36.73	43.92	53.26
	20.17	17.58	9.92	9.57	11.58	13.74
	58.97	52.10	31.84	27.16	32.34	39.52
	69.32	61.24	37.43	31.93	38.02	46.45
Key metrics
	99.77	87.10	55.71	51.60	60.21	65.23
	33.11%	29.80%	19.40%	18.10%	23.70%	29.70%
	19.57%	17.80%	11.10%	9.50%	12.70%	18.00%
	—	16.50%	10.50%	—	—	—
	8.97%	2.00%	0.50%	12.30%	15.80%	—
	88.70%	63.60%	17.20%	-16.00%	-18.20%	—
	—	33.60	43.34	—	—	—
	—	0.98	2.01	—	—	—
	—	0.19	0.31	—	—	—
	—	73.68	103.71	—	—	—
	—	164.2	135.8	—	—	—
Balance sheet
	—	557.35	546.00	—	—	—
	—	189.76	185.24	—	—	—
	—	0.79	0.55	—	—	—
	—	92.04	80.59	—	—	—
	—	59.98	58.51	—	—	—
	—	13.62	18.73	—	—	—
	—	287.61	104.83	—	—	—
	—	20.56	32.53	—	—	—
	—	91.92	96.70	—	—	—
	—	74.47	104.26	—	—	—
	—	52.79	52.95	—	—	—
	—	21.68	51.31	—	—	—
	—	385.18	339.09	—	—	—
Cash flow
	—	50.92	63.97	—	—	—
	—	-2.36	-19.04	—	—	—
	—	-48.31	-46.35	—	—	—
	—	17.32	20.63	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +4.77%
Sales CAGR 5Y: —
Profit CAGR 3Y: +17.23%
Profit CAGR 5Y: —
Sales YoY (TTM): +8.97%
Profit YoY (TTM): +88.70%

Consolidated

Sales CAGR 3Y: +7.72%
Sales CAGR 5Y: —
Profit CAGR 3Y: +27.03%
Profit CAGR 5Y: —
Sales YoY (TTM): +4.09%
Profit YoY (TTM): +254.35%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 44.29%

Quarter	September 2026	June 2026
Promoter %	44.29%	53.74%

Holder	Type	Holding	Previous	Change
Rajiv Dinesh Gandhi	Promoter	10.48%	10.48%	0.00%
Sanjiv Dinesh Gandhi	Promoter	8.20%	8.20%	0.00%
Nina Rajiv Gandhi	Promoter	8.19%	8.19%	0.00%
Shaila Bhupendra Gandhi	Promoter	5.78%	5.78%	0.00%
Ravin Gandhi	Public	4.74%	4.74%	0.00%
Bela Gandhi	Public	4.71%	4.71%	0.00%
Bhupendra Vithaldas Gandhi	Promoter	4.68%	4.68%	0.00%
Kuntal Hasmukhlal Shah	Public	3.17%	3.17%	0.00%
Biolink Healthcare Limited	Promoter Group	2.93%	2.93%	0.00%
Manish Jain	Public	2.88%	2.88%	0.00%
Anup Chandravadan Kapadia	Promoter	2.68%	2.68%	0.00%
Darshna Dinesh Kapadia	Public	1.81%	1.81%	0.00%
Sandeep Shantilal Gala	Public	1.30%	1.30%	0.00%
Vinay Shah	Public	1.28%	1.28%	0.00%
Manish Jain (HUF)	Public	1.23%	1.23%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Hester Biosciences Ltd	1,973	2,318.85	14.41	15.30%	+4.09% TTM	+254.35% TTM	+44.58%

Filings & corporate actions

Recent announcements

This is to inform you that, as per Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has scheduled investor ....28 Oct 2026 · Company Update / Analyst / Investor Meet
Hester Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve unaudited standalone and ....27 Oct 2026 · Board Meeting / Board Meeting
Disclosure under Regulation 30 of the SEBI Listing Regulations - Completion of tenure of Independent Director Mr. Ameetkumar Desai with effect from closure of business hours on 27 October ....27 Oct 2026 · Company Update / General
Confirmation Certificate for the quarter ended 30 September 202614 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Disclosure under Regulation 30 of the SEBI Listing Regulation for Investment in Limited Liability Partnership for Group Captive Power Generation6 Oct 2026 · Company Update / General
Outcome of Board Meeting and Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Investment in Limited Liability Partnership ....6 Oct 2026 · Others / Outcome without intimation
Closure of Trading Window25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Shareholders'' approval for Reclassification of Mr. Ravin Gandhi and Ms. Bela Gandhi from Promoter and Promoter Group category to Public Category shareholders of the Company.4 Sep 2026 · Company Update / General
Scrutinizer''s Report for Postal Ballot Process4 Sep 2026 · AGM/EGM / Postal Ballot
Outcome, proceedings and Voting Results of Postal Ballot Process for the Notice dated 30 July 20264 Sep 2026 · AGM/EGM / Postal Ballot
Intimation of Upgrade in Credit Ratings by Care Ratings Limited27 Aug 2026 · Company Update / Credit Rating
Postal Ballot Notice4 Aug 2026 · AGM/EGM / Postal Ballot
Transcript of Earnings Conference Call held on 30 July 20261 Aug 2026 · Company Update / Analyst / Investor Meet
Launch of Interactive Microsite of 39th Annual Report FY 2025-2631 Jul 2026 · Company Update / General
Newspaper Clippings of Q1 FY27 Financial Results publication31 Jul 2026 · Company Update / Newspaper Publication
Audio recording of the Earnings Conference Call held on 30 July 202630 Jul 2026 · Company Update / Analyst / Investor Meet
20260730 Q1 FY27 Press Release30 Jul 2026 · Company Update / Press Release / Media Release
Financial Results and Press Release for the Quarter ended 30 June 202630 Jul 2026 · Result / Financial Results
Outcome of Board Meeting held today30 Jul 2026 · Board Meeting / Outcome of Board Meeting
Intimation of Earnings Conference Call schedule to be held on 30 July 2026 at 2:00 p.m. (IST) post the publication of financial results25 Jul 2026 · Company Update / Analyst / Investor Meet
We wish to inform that NSE and BSE has issued their NOC for the re-classification application filed on 19 May 2026.The copies of NOC enclosed herewith.25 Jul 2026 · Company Update / General
Hester Biosciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve the unaudited standalone ....23 Jul 2026 · Board Meeting / Board Meeting
Voting Results of 39th Annual General Meeting and Scrutiniser Report21 Jul 2026 · AGM/EGM / AGM
Outcome of 39th Annual General Meeting, Voting Results and Scrutinizer Report of the Company21 Jul 2026 · AGM/EGM / AGM
Disclosure under Regulation 30 of the SEBI Listing Regulations - Sale of Equity Investment in Texas Lifesciences Private Limited9 Jul 2026 · Company Update / General
Newspaper publication dated 9 July 2026 for the Transfer of Equity Shares of the Company to IEPF on compliance of IEPF Rules9 Jul 2026 · Company Update / Newspaper Publication
Newspaper clipping for the publication dated 9 July 2026 for Corrigendum to the Notice convening 39th Annual General Meeting9 Jul 2026 · Company Update / Newspaper Publication
Confirmation Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30 June 20268 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Corrigendum to the Notice convening 39th Annual General Meeting of the Company8 Jul 2026 · AGM/EGM / AGM
Closure of Trading Window26 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Copies of newspaper advertisement for 39th Annual General Meeting19 Jun 2026 · Company Update / Newspaper Publication
FY 2025-26 Business Responsibility and Sustainability Report18 Jun 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Record date for Dividend and AGM is Tuesday, 14 July 2026, for the purpose of determining shareholders'' entitlement for dividend, as recommended by the Board of Directors at their meeting ....18 Jun 2026 · Corp. Action / Record Date
Hester''s 39th Annual Report 2025-2618 Jun 2026 · Others / Reg. 34 (1) Annual Report
Hester''s 39th Annual General Meeting to be held on 21 July 2026 through Video Conference/ Other Audio Visual Means. Hester''s 39th Annual Report 2025-26 and AGM notice attached herewith.18 Jun 2026 · AGM/EGM / AGM
Announcement under Regulation 30 of Listing Regulation - Amendments in Loan agreement of Hester Africa20 May 2026 · Company Update / General
Intimation of Submission of reclassification application with the stock exchanges under Regulations 31A of Listing Regulations20 May 2026 · Company Update / General
Annual Secretarial Compliance Report for the year ended 31 March 202618 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Transcript of Earnings Conference Call held on 15 May 202618 May 2026 · Company Update / Analyst / Investor Meet
Newspaper clippings of Financial Results for Q4 & FY26 ended 31 March 202618 May 2026 · Company Update / Newspaper Publication

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 11.0000	14 Jul 2026	14 Jul 2026	—
Final Dividend - Rs. - 7.0000	6 Aug 2025	6 Aug 2025	—
Dividend - Rs. - 6.0000	22 Aug 2024	—	—

Board meetings

5 Nov 2026 Board Meeting - Financial Results
30 Jul 2026 Board Meeting - Financial Results